Cengild Medical BhdXKLS:0243 67 EBITDA Margin % is 25.68% as of Mar. 2026, which is 15% below its 10-year median of 30.18. GuruFocus rates XKLS:0243 with a GF Score™ of 67/100 and a GF Value™ of RM0.29 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 666 Healthcare Providers & Services companies, Cengild Medical Bhd ranks better than 87.39% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cengild Medical Bhd's EBITDA for the
three
months ended in Mar. 2026 was RM4.24 Mil. Cengild Medical Bhd's Revenue for the
three
months ended in Mar. 2026 was RM16.51 Mil. Therefore, Cengild Medical Bhd's EBITDA margin for the quarter that ended in Mar. 2026 was 25.68%.
Cengild Medical Bhd (XKLS:0243) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cengild Medical Bhd EBITDA Margin % Related Terms
Cengild Medical Bhd EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cengild Medical Bhd's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0243 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Cengild Medical Bhd's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cengild Medical Bhd EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cengild Medical Bhd's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cengild Medical Bhd's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cengild Medical Bhd (XKLS:0243) has a EBITDA Margin % of 25.68% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cengild Medical Bhd and its competitors. This is 15% below median its historical median of 30.18. Over the past decade, Cengild Medical Bhd's EBITDA Margin % has ranged from 12.85 to 31.94. According to the industry distribution chart, Cengild Medical Bhd ranks #84 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 12.6%.
Is Cengild Medical Bhd's EBITDA Margin % too high?
Cengild Medical Bhd's current EBITDA Margin % of 25.68% is 15% below median its 10-year median of 30.18. Over the past 10 years, this metric has ranged from a low of 12.85 to a high of 31.94. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Cengild Medical Bhd's value of 25.68% is 151.5% above this industry median. Based on the distribution chart, Cengild Medical Bhd ranks #84 out of 666 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Cengild Medical Bhd has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cengild Medical Bhd's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Cengild Medical Bhd ranks #84 out of 666 companies for EBITDA Margin %. This places Cengild Medical Bhd in the top 13% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Cengild Medical Bhd's value of 25.68% is 151.5% above this benchmark. Historically, Cengild Medical Bhd's own EBITDA Margin % has ranged from 12.85 to 31.94 over the past decade. While the company's 10-year median is 30.18 vs. the industry median of 10.21, Cengild Medical Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cengild Medical Bhd's current EBITDA Margin % of 25.68% is 151.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cengild Medical Bhd and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cengild Medical Bhd's current EBITDA Margin % is 25.68%, which is 15% below median its own 10-year median of 30.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cengild Medical Bhd stock overvalued right now?
Based on GuruFocus' analysis, Cengild Medical Bhd (XKLS:0243) is currently considered Significantly Undervalued. The stock's GF Value™ is RM0.29, compared to a current price of RM0.20 — trading 31% below its estimated fair value. The current EBITDA Margin % is 25.68%, which is 15% below median its 10-year median of 30.18 and 151.5% above the Healthcare Providers & Services industry median of 10.21. Cengild Medical Bhd's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cengild Medical Bhd (XKLS:0243), the current EBITDA Margin % is 25.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cengild Medical Bhd (XKLS:0243) Overvalued in 2026?
Based on GuruFocus' analysis, Cengild Medical Bhd stock appears to be undervalued.
The current stock price of RM0.20 is trading 31% below its estimated GF Value™ of RM0.29.
GuruFocus considers Cengild Medical Bhd to be Significantly Undervalued.
Key valuation signals for XKLS:0243:
EBITDA Margin %: 25.68% (15% below median its 10-year median of 30.18)
GF Value™: RM0.29 vs. price of RM0.20 (31% below fair value)
Industry Position: 151.5% above the Healthcare Providers & Services median (#84 of 666)
No single metric tells the full story. See the XKLS:0243 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cengild Medical Bhd is a healthcare service provider operating a medical centre specializing in the diagnosis and treatment of gastrointestinal-related diseases, oncology, gynecology services., liver diseases, and obesity. The company operates in Malaysia and has two reportable segments, Consultant Services and Medical Management Services. A substantial portion of the overall revenue is generated from its Medical Management Services segment.
67GF Score
Get the complete analysis for XKLS:0243
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0243 has been successfully added to your 
